{"entity":{"id":"interception-vaccination","kind":"technology","name":"Cancer interception vaccines","aka":[],"tldr":"Cancer interception vaccines immunise people who do not yet have cancer but carry a high inherited risk, such as Lynch syndrome carriers, against the antigens their future tumour is predicted to express, so memory T cells remove transformed cells early. Because healthy people accept risk for a probabilistic benefit, the safety bar is far higher and trials take years.","summary":"Lynch syndrome tumours share recurrent frameshift neoantigens, making a shared off-the-shelf vaccine possible; Nous-209 has been tested in Lynch carriers, and a preventive vaccine against alpha-lactalbumin is in early trials for triple-negative breast cancer at the Cleveland Clinic. The strategy asks a healthy person to accept risk for a probabilistic benefit, so the safety bar is far higher and trials need long follow-up with adenoma or lesion endpoints.","status":"phase-2","asOf":"2026-09-08","links":[{"label":"ClinicalTrials.gov: Lynch syndrome vaccine","url":"https://clinicaltrials.gov/search?term=Lynch%20syndrome%20vaccine"}],"tags":["frontier","radical"],"related":[],"cancers":["colorectal","tnbc"],"sections":["prevention","immunotherapy"],"technologies":["shared-antigen-vaccine","chemoprevention","germline-testing","hpv-vaccine"],"targets":["brca"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Immunising against antigens a future tumour is predicted to express creates memory T cells that eliminate transformed cells before a clinical cancer forms.","strengths":["Intact immune system and zero tumour burden","Shared antigens allow an off-the-shelf product","Cost-effective even if only modestly effective"],"limitations":["Long, expensive trials with surrogate endpoints","Very high safety bar in healthy people","Autoimmunity risk against self-antigens"]},"route":"/technologies/interception-vaccination/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"}],"technology":[{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/"},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/"},{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/"},{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"}],"roadmap":[{"id":"prevention-roadmap","kind":"roadmap","name":"Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers","route":"/roadmaps/prevention-roadmap/"},{"id":"cure-paths","kind":"roadmap","name":"Paths to cures: interception, eradication, control","route":"/roadmaps/cure-paths/"}],"paper":[{"id":"paper-lynch-frameshift-vaccine-ccr-2020","kind":"paper","name":"First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers","route":"/key-papers/paper-lynch-frameshift-vaccine-ccr-2020/"}],"drug":[{"id":"hpv-bivalent-vaccine","kind":"drug","name":"HPV bivalent vaccine (types 16 and 18)","route":"/drugs/hpv-bivalent-vaccine/"},{"id":"hpv-quadrivalent-vaccine","kind":"drug","name":"HPV quadrivalent vaccine (types 6, 11, 16 and 18)","route":"/drugs/hpv-quadrivalent-vaccine/"}],"term":[{"id":"ageing-tissue-field-theory","kind":"term","name":"Ageing tissue and clonal fields: cancer as a disease of old tissue","route":"/terms/ageing-tissue-field-theory/"}],"trial":[{"id":"nct06465914","kind":"trial","name":"A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males","route":"/trials/nct06465914/"},{"id":"nct04422366","kind":"trial","name":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","route":"/trials/nct04422366/"}]}}